Email:
global@GCP-ClinPlus.com
GCP ClinPlus is honored to have been the CRO partner for OcuMension’s anti-VEGF drug OT-702, delivering comprehensive data management, statistical programming, and biostatistics support throughout its development. Our collaboration contributed to the therapy’s successful NMPA approval for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
How GCP ClinPlus Ensured High-Quality Delivery with AI & Data Science:
✓ Implemented an AI-integrated analytical framework to strengthen statistical inference and regulatory alignment
✓ Complied with international standards, maintaining complete data traceability and end-to-end quality control
✓ Devoted over 6,922 hours, with a 95-member expert team supporting 13 regulatory submissions
✓ Supported 210+ successful product approvals, demonstrating proven expertise in innovative drug development
Partner with GCP ClinPlus to advance your drug’s pathway with data intelligence and global-quality execution.
Contact us: global@gcp-clinplus.com